Does platelet storage time affect protection from bleeding in blood cancer patients?
Official title: Clinical Efficacy of Platelet Transfusion
Run by Centre Hospitalier Universitaire de Besancon · NCT06805097 · Data updated 2026-11-12
This project tests whether how long donated platelets are stored (about 5 days versus longer) changes bleeding risk for people with blood cancers and very low platelet counts.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 343 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Besancon Academic / other |
| Locations | 1 site (Besançon) |
| Status | Recruiting |
| Started | June 17, 2025 |
| Main results expected | July 2028 |
| Study ends | July 2028 |
| Registry record updated | July 9, 2025 |
| Trial ID | NCT06805097 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with haematological malignancies or bone marrow aplasia who have severe thrombocytopenia requiring prophylactic platelet transfusion, can self-report bleeding events, are covered by the French social security system, and agree to participate.
✕Probably not a fit
Patients with acute promyelocytic leukaemia, immune-mediated thrombocytopenia or disseminated intravascular coagulation, those on curative-dose anticoagulants or antiplatelet drugs, with recent significant bleeding, pregnant or breastfeeding women, or adults under legal protection are excluded and unlikely to benefit from this comparison.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Since 2017 changes in platelet preparation and shelf life have altered the number and composition of platelet concentrates transfused to patients. The ECLAT study is a prospective multicentre observational cohort that compares haemorrhagic events in haematology patients with severe thrombocytopenia according to the duration of platelet concentrate storage (shorter versus longer than 5 days). Bleeding events are recorded by patient self-assessment alongside clinical data to link transfusion characteristics with outcomes. The design focuses on real-world transfusions given for prophylaxis in patients with haematological malignancies or bone marrow aplasia.
Why it matters
Potential benefit: If successful, the findings could help blood banks and clinicians choose optimal platelet storage times to reduce bleeding and use platelets more effectively.
How similar studies have gone: Previous work shows longer platelet storage reduces in vivo recirculation but generally has not shown clear effects on haemostatic outcomes, and the specific comparison of platelets stored ≤5 days versus >5 days has not been evaluated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with haematological malignancies or bone marrow aplasia with severe thrombocytopenia due to bone marrow failure related to the disease or treatments received * Severe thrombocytopenia requiring transfusion * Patient able to self-assess bleeding events * Non-opposition of the subject to participate in the study * Registered with the French social security system or benefiting from such a system. Exclusion Criteria: * Acute promyelocytic leukaemia * Curative dosage of anticoagulants * Treatment with antiplatelet agents * Patient with proven thrombocytopenia of immunological origin, or disseminated intravascular coagulation * Patients with a clinically significant haemorrhagic event (WHO grade 2) in the 48 hours prior to transfusion * Indication for deplasmatised, cryopreserved and reduced-volume PCs * Patient refusing transfusion of labile blood products * Pregnant women or breast-feeding mothers * Adults subject to a legal protection measure or unable to express their consent * Persons deprived of their liberty by a judicial or administrative decision; persons under compulsory psychiatric care; persons admitted to a health or social care institution for purposes other than research * Subject in the exclusion period of another study
Where it's running
-
CHU Besançon
Besançon, France Recruiting
Study contacts
- Study coordinator: Charline Vauchy, PhD.
- Email: cvauchy@chu-besancon.fr
- Phone: +33381218875
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preoperative romiplostim to raise platelets before cardiac surgery
This test tries whether a short course of romiplostim can raise platelet counts so adults with low platelets can safely have cardiac surgery with cardiopulmonary bypass.
-
Transplanting cryopreserved ovarian tissue in cancer survivors
This study is testing whether ovarian tissue from cancer survivors is safe to transplant by checking for any leftover cancer cells, which could help restore their fertility.
-
Decentralized care pathway for cancer patients receiving oral treatment
This study is testing a new way for cancer patients on oral chemotherapy to receive care at home from a nurse instead of going to the hospital, to see if it makes them happier and helps them stick to their treatment.
-
Using sirolimus to treat thrombocytopenia related to antiphospholipid antibodies
This study is testing if the medication sirolimus can help people with low platelet counts caused by antiphospholipid antibodies feel better compared to those who receive a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.